Double-blind trial of P1G10 from V. cundinamarcensis on chronic neuropathic wounds in diabetic foot ulcers
Diabetic Foot · Diabetic Neuropathy · Foot Ulcer
Enrolment: 50 · Results not recorded
Loading the evidence…
Biologic · Cysteine proteinase fraction from Vasconcellea cundinamarcensis (Carica candamarcensis) latex; a crude proteolytic fraction with no ChEMBL entity. Direct human evidence: a completed phase 2 double-blind trial of P1G10 hydrogel in diabetic foot ulcers, an exact match to the named therapy.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Diabetic Foot · Diabetic Neuropathy · Foot Ulcer
Enrolment: 50 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Single acute ultraviolet B skin exposure at 2.4 J/cm2
Topical P1G10 reduced erythema, increased hypodermal cellularity, reversed ultraviolet B induced depletion of antioxidant defences, lowered malondialdehyde, and inhibited MMP-9 and caspase-3 while increasing p53.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.